Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31103976 | 1.00 | CES2 (0.32) | CES2CES1MEP1BGPR84 | |
| SCHEMBL383805 | 0.85 | TRPA1 (0.32) | — | |
| SCHEMBL4678400 | 0.82 | MEP1B (0.32) | MEP1B | |
| SCHEMBL3310091 | 0.82 | GPR84 (0.31) | GPR84 | |
| SCHEMBL3024241 | 0.82 | ALDH1A1 (0.36) | — | |
| SCHEMBL25049411 | 0.82 | CYP1A2 (0.31) | — | |
| SCHEMBL4976489 | 0.80 | MEP1B (0.49) | MEP1B | |
| SCHEMBL488065 | 0.80 | MPO (0.37) | — | |
| SCHEMBL378747 | 0.80 | ACHE (0.32) | — | |
| SCHEMBL14577004 | 0.80 | TAAR1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119465288-A | Anion exchange membrane, preparation method and application thereof, and electrolysis device | 氢和元泰(常州)新材料科技有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | AVILAR THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| CN-119465288-A | Anion exchange membrane, preparation method and application thereof, and electrolysis device | 氢和元泰(常州)新材料科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2022258052-A1 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022047230-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| CN-112041296-A | Aminoacetamides containing benzo-oxy-alicyclic structure and use thereof | 上海璃道医药科技有限公司 | 2020-12-04 | — | — | CN | disclosed |
| US-10662185-B2 | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-05-26 | — | — | US | disclosed |
| WO-2004026827-A1 | PYRROLIDONE DERIVATIVES AS MAOB INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-01 | — | — | WO | disclosed |
| WO-2004011443-A1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
| CN-1443164-A | Pyrrolidine derivatives as metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2003-09-17 | — | — | CN | disclosed |
| EP-1083897-A4 | HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6306891-B1 | INHIBITORS OF HIV INTEGRASE AND INHIBITORS OF HIV REPLICATION. THESE COMPOUNDS ARE USEFUL IN THE PREVENTION OR TREATMENT OF INFECTION BY HIV TREATMENT OF AIDS, EITHER AS COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS | MERCK & CO., INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1083897-A1 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062513-A1 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| US-5409943-A | [(alkoxy)pyridinyl]amine compounds which are useful in the treatment of gastrointestinal disorders | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1995-04-25 | — | — | US | disclosed |
| EP-0625143-A1 | PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1994-11-23 | — | — | EP | disclosed |
| WO-1993015055-A1 | PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131007-A1 | Mannose 6-Phosphate Receptor Binding Compounds for the Degradation of Extracellular Proteins | IGF2R, M6PR, MSR1 | CES2 2735/4885CES1 3124/4885MEP1B 371/4885 |
| US-10662185-B2 | Amino-substituted imidazo[1,2-A] pyridinecarboxamides and their use | AADAC, TNNI3, TNNT2 | CES2 460/4885CES1 60/4885MEP1B 1315/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | CES2 630/4885CES1 430/4885MEP1B 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.